The market has become lucrative for local and foreign corporations alike. It has encouraged foreign companies who have already penetrated the market to continuously expand and cover other developing regions. It has also invited multinational firms to consider designing an entry strategy to capitalize on this growth.

 

Despite this massive opportunity for pharmaceutical, medical devices and consumables, insurance and other healthcare companies, the China healthcare market remains a convoluted web in identifying the appropriate strategies that should be undertaken.

 

Government regulations on registration, certification and product entry occur from both municipal to national levels. Advancement in medical knowledge acquisition and economic conditions of the city or province, results in varying availabilities of both healthcare products and services across locations, with higher-tier cities being the primary targets for initial entry and lower-tier, developing cities for further expansion.

 

Whilst commercialization dynamics exhibit both local and national features, distribution and pricing is locally driven. This makes it imperative for any player to first understand these structures in order to effectively establish a foothold in any target location.

 

At the same time, insurance-related reimbursements, which strongly influence market entry capabilities and patient preferences, are locally developed, yielding multiple tiers of financing considerations.

 

In this dynamic and complex environment, our investigative, bottom-up approach to primary research is highly effective in helping you develop a suitable market entry or growth strategy for your business.

 

Our goal is to help clients find new opportunities to grow their existing business and offer end-to-end strategy consulting services from initial market assessment to implementation.